Canada Tackles AMR With Drug Reserve List; Incentive Recommended To Motivate Antibiotic Development
A report advising Canada to adopt a subscription pull model to incentivize antibiotic drug development has also highlighted that only three of the 18 new antibiotics that entered the global market between 2010 and 2019 were marketed in Canada as of May 2023. Meanwhile, Health Canada is seeking feedback on its antimicrobial drug reverse list.
You may also be interested in...
Applications from drug companies should also include a commercial proposal, says Pharmac.
Health technology assessment institute NICE is scheduled to appraise Eisai/Biogen’s lecanemab and Eli Lilly’s donanemab next year.
While things are starting to look up for the commercial clinical trial ecosystem in the UK, more progress is needed to improve industry’s confidence in the country as a destination for research, especially revenue-generating Phase III trials.